Analysts Set Alto Neuroscience, Inc. (NYSE:ANRO) Price Target at $15.40

Alto Neuroscience, Inc. (NYSE:ANRO) has received an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $15.40.

ANRO has been the topic of several recent research reports. HC Wainwright started coverage on shares of Alto Neuroscience in a research note on Monday, April 7th. They set a “buy” rating and a $10.00 target price on the stock. William Blair reaffirmed an “outperform” rating on shares of Alto Neuroscience in a research note on Friday, March 21st.

Hedge Funds Weigh In On Alto Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP acquired a new position in shares of Alto Neuroscience during the 4th quarter worth about $3,542,000. Point72 Asset Management L.P. lifted its holdings in shares of Alto Neuroscience by 73.1% during the fourth quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock worth $7,158,000 after purchasing an additional 714,461 shares during the period. Franklin Resources Inc. increased its stake in Alto Neuroscience by 95.3% in the 3rd quarter. Franklin Resources Inc. now owns 1,220,712 shares of the company’s stock valued at $13,965,000 after buying an additional 595,673 shares during the period. Woodline Partners LP boosted its stake in shares of Alto Neuroscience by 397.6% in the fourth quarter. Woodline Partners LP now owns 621,976 shares of the company’s stock valued at $2,631,000 after buying an additional 496,976 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Alto Neuroscience by 198.1% during the 4th quarter. Northern Trust Corp now owns 587,135 shares of the company’s stock valued at $2,484,000 after acquiring an additional 390,190 shares during the period.

Alto Neuroscience Stock Performance

Shares of Alto Neuroscience stock opened at $2.22 on Friday. Alto Neuroscience has a 52 week low of $1.60 and a 52 week high of $17.55. The company has a 50 day moving average price of $2.41 and a 200 day moving average price of $3.46. The company has a quick ratio of 13.09, a current ratio of 13.10 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $60.10 million, a P/E ratio of -0.87 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.06. Sell-side analysts expect that Alto Neuroscience will post -2.54 EPS for the current year.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.